Leukogene Therapeutics
PrivateLast Round
Seed
Nov 12, 2025
Total Funding Raised
$2.63M
Company Overview
Leukogene Therapeutics operates in Healthcare & Life Sciences and is based in Charleston, South Carolina. Its latest recorded funding round was a Seed round in November 2025.
Leukogene Therapeutics is a biopharmaceutical company developing MHC class II-targeted recombinant protein immunotherapies to treat hematologic and other immunologically “cold” cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Leukogene Therapeutics Comparables
Compare Leukogene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asylia Therapeutics | 82% | |
| Amgen | 71% | |
| Johnson & Johnson | 69% |
For institutional investors. Book with your work email.
Leukogene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 12, 2025 | ||||
| Seed | Sep 9, 2025 | ||||
| Grant | Aug 30, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Leukogene Therapeutics Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2025
Raised Seed round with participation from 1824healthventures.
- Aug 30, 2018
Raised $2M in grant funding.
For institutional investors. Book with your work email.
Leukogene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Leukogene Therapeutics's valuation, stock price, and market status.
Is Leukogene Therapeutics a public or private company?
Leukogene Therapeutics is a private company.
What is the current stock price of Leukogene Therapeutics?
Leukogene Therapeutics is a private company, so its shares have no public market price. Caplight tracks Leukogene Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Leukogene Therapeutics worth (valuation)?
Valuation information for Leukogene Therapeutics is not publicly available.
Can I buy Leukogene Therapeutics stock?
Leukogene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Leukogene Therapeutics's last funding round?
Leukogene Therapeutics's most recent funding round was Seed on November 12, 2025.
Who are the main investors in Leukogene Therapeutics?
Key investors in Leukogene Therapeutics include SC Launch, SCRA.
Will Leukogene Therapeutics IPO soon?
No public IPO plans have been announced for Leukogene Therapeutics.
How can I track Leukogene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Leukogene Therapeutics's shares on secondary markets.